A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste

Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
doi: https://doi.org/10.1101/2022.01.28.22270035

Article Information

doi 
https://doi.org/10.1101/2022.01.28.22270035
History 
  • January 31, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Geoffrey Chupp, M.Da,
  2. Anne Spichler-Moffarah, M.D, Ph.D.b,
  3. Ole S. Søgaard, M.D, Ph.D.c,
  4. Denise Esserman, Ph.D.d,
  5. James Dziura, Ph.D.d,
  6. Lisa Danzig, M.D., M.P.H.e,
  7. Reetika Chaurasia, Ph.D.b,
  8. Kailash P. Patra, Ph.D.b,
  9. Aryeh Salovey, B.S.b,
  10. Angela Nunez, MPHf,
  11. Jeanine May, APRNf,
  12. Lauren Astorino, APRNf,
  13. Amisha Patel, B.S.g,
  14. Stephanie Halene, M.D., Ph.D.g,
  15. Jianhui Wang, Ph.D.h,
  16. Pei Hui, Ph.D., M.D.h,
  17. Prashant Patel., Pharm.Di,
  18. Jing Lu, Ph.D., R.Ph.i,
  19. Fangyong Li, M.P.H., M.S.d,
  20. Geliang Gan, M.S.d,
  21. Stephen Parziale, M.Sc.d,
  22. Lily Katsovich, M.S., M.B.A.d,
  23. Gary V. Desir, M.D.i and
  24. Joseph M. Vinetz, M.D.b,*
  1. aSection of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
  2. bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
  3. cDepartment of Clinical Medicine and Department of Infectious Diseases, Aarhus University, Aarhus, Denmark
  4. dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
  5. eAmicitiam Partners, San Francisco, CA
  6. fYale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT, USA
  7. gSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
  8. hDepartment of Pathology, Yale School of Medicine New Haven, CT, USA
  9. iInvestigation Drug Service, Yale New Haven Hospital, New Haven, CT, USA
  10. jDepartment of Internal Medicine, Yale School of Medicine New Haven, CT, USA
  1. ↵*Correspondence to Joseph M. Vinetz, M.D., Yale School of Medicine, 25 York St., Winchester 403D, New Haven, CT, USA 06520-8022, Email: joseph.vinetz{at}yale.edu, Tel. 203-737-9730
Back to top
Posted January 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
medRxiv 2022.01.28.22270035; doi: https://doi.org/10.1101/2022.01.28.22270035
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area